TLR4 agonists can drive potent antitumor immunity, but their clinical use has been constrained by systemic toxicities. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results